for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Tocagen Inc

TOCA.O

Latest Trade

0.60USD

Change

0.00(+0.63%)

Volume

143,700

Today's Range

0.58

 - 

0.62

52 Week Range

0.53

 - 

14.75

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.60
Open
0.60
Volume
143,700
3M AVG Volume
16.74
Today's High
0.62
Today's Low
0.58
52 Week High
14.75
52 Week Low
0.53
Shares Out (MIL)
23.90
Market Cap (MIL)
15.51
Forward P/E
-0.25
Dividend (Yield %)
--

Next Event

Q3 2019 Tocagen Inc Earnings Release

Latest Developments

More

Tocagen Begins Restructuring Plan That Includes Cutting Workforce By About 65%

Tocagen Reports Results Of Toca 5 Phase 3 Trial In Recurrent Brain Cancer

Tocagen Reports Q2 Loss Per Share $0.72

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Tocagen Inc

Tocagen Inc. (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells. Its lead product candidates are vocimagene amiretrorepvec (Toca 511) and flucytosine extended release (Toca FC). Toca 511 is an investigational injectable retroviral replicating vector (RRV) that encodes a prodrug activator enzyme, cytosine deaminase (CD). Toca FC is an investigational extended-release version of 5-fluorocytosine (5-FC), a prodrug that is inactive as an anti-cancer drug. As of February, 2017, Tocagen has completed enrollment of the Phase II portion with 187 patients.

Industry

Biotechnology & Drugs

Contact Info

4242 Campus Point Ct Ste 500

+1.858.4128400

https://tocagen.com

Executive Leadership

Faheem Hasnain

Independent Chairman of the Board

Martin J. Duvall

Chief Executive Officer, Director

Mark G. Foletta

Chief Financial Officer, Executive Vice President

Harry E. Gruber

President - Science and Innovation, Director

Douglas Jolly

Executive Vice President - Research and Pharmaceutical Development

Key Stats

3.00 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2017

-2.660

2018

-2.440

2019(E)

-2.595
Price To Earnings (TTM)
--
Price To Sales (TTM)
0.86
Price To Book (MRQ)
0.43
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
72.59
LT Debt To Equity (MRQ)
60.51
Return on Investment (TTM)
-76.59
Return on Equity (TTM)
-62.80

Latest News

Latest News

UPDATE 2-Tocagen's brain cancer treatment fails late-stage study, shares crash

Tocagen Inc's shares fell nearly 80% after its experimental treatment failed to extend life of brain cancer patients in a study, the latest in a series of setbacks for patients awaiting new treatment options for the condition.

Tocagen's brain cancer treatment fails late-stage study

Tocagen Inc said on Thursday its experimental treatment did not prove effective in helping patients with a type of brain cancer to live longer, in a late-stage study.

BRIEF-Tocagen Entered Amended And Restated Loan And Security Agreement For $26.5 Mln

* TOCAGEN - ENTERED AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT FOR $26.5 MILLION AS TERM LOANS FUNDED ON EFFECTIVE DATE - SEC FILING Source text: (https://bit.ly/2IEQjX8) Further company coverage:

BRIEF-Tocagen Reports Q1 Loss Per Share $0.65

* TOCAGEN REPORTS FIRST QUARTER 2018 FINANCIAL AND BUSINESS RESULTS

BRIEF-Tocagen And ApolloBio Enter License Agreement To Develop Toca 511 & Toca FC In Greater China

* TOCAGEN AND APOLLOBIO ENTER LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE TOCA 511 & TOCA FC IN THE GREATER CHINA REGION

BRIEF-Tocagen Q4 Loss Per Share $0.55

* TOCAGEN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL AND BUSINESS RESULTS

BRIEF-Tocagen Receives EMA Orphan Medicinal Product Designation For Toca 511 & Toca FC For Glioma Treatment

* TOCAGEN RECEIVES EUROPEAN MEDICINES AGENCY ORPHAN MEDICINAL PRODUCT DESIGNATION FOR TOCA 511 & TOCA FC FOR THE TREATMENT OF GLIOMA Source text for Eikon: Further company coverage:

BRIEF-Tocagen Estimates Cash, Cash Equivalents And Marketable Securities About $89.0 Million As Of Dec 31, 2017

* TOCAGEN SAYS ESTIMATE CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE ABOUT $89.0 MILLION AS OF DEC 31, 2017 - SEC FILING

BRIEF-Tocagen Q3 loss per share $0.50

* Tocagen reports third quarter 2017 financial and business results

BRIEF-Tocagen to accelerate Toca 511 & Toca FC development into Phase 3 trial

* Tocagen to accelerate Toca 511 & Toca FC development into pivotal Phase 3 trial Source text for Eikon: Further company coverage:

BRIEF-Tocagen Q2 loss per share $0.56

* Tocagen reports second quarter 2017 financial and business results

BRIEF-Tocagen reports quarterly loss per share $0.56

* Qtrly license revenue $10,000 versus $13,000 Source text: (http://bit.ly/2wuNluv) Further company coverage:

BRIEF-Tocagen receives PRIME designation for Toca 511

* Tocagen receives European Medicines Agency Priority Medicines (PRIME) designation for Toca 511 in high grade Glioma Source text for Eikon: Further company coverage:

BRIEF-Tocagen Q1 loss per share $4.11

* Tocagen reports first quarter 2017 financial and business results

BRIEF-EcoR1 Capital LLC reports 7.6 pct passive stake in Tocagen

* EcoR1 Capital LLC reports 7.6 percent passive stake in Tocagen Inc as of April 13 - sec filing Source text : http://bit.ly/2pzZABZ Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up